Key Takeaways
- Revenue hit by Red Sea, not demand: Revenue fell 11% QoQ to ₹163 cr solely because DAP revenue recognition deferred sales into Q2; underlying dispatches exceeded Q4 levels and customer demand remains intact.
- PI segment breakout quarter: The pharma intermediates segment grew 60% QoQ as the cardiovascular intermediate for an innovator customer ramped up, with new capacity now live and validation batches successfully passed.
- Gross margin improved despite mix headwind: Gross margin rose 140 bps QoQ even as high-margin contrast media share fell from 62% to 40%, helped by lower raw material costs and a favorable building-block mix.
- Capacity build-out is contractually anchored: ₹200 cr of committed capex over 12–18 months adds 40–50% more capacity, much of it backed by existing customer visibility; a greenfield site is being initiated because existing facilities are saturated.
- What to watch next quarter: Whether the deferred Q1 revenue reverses into Q2, the ramp-up of the cardiovascular intermediate from Q3, and any formal PO for the contrast media forward-integration product.
Revenue Deferral: The Red Sea Effect
- Mechanics of the miss: Transit time to customers doubled from 35–40 days to 65–70 days due to Red Sea rerouting, so goods dispatched in Q1 that exceeded Q4 levels could not be recognized as revenue under DAP terms, where recognition happens only upon customer receipt.
- Contrast media bore the brunt: Segment turnover fell 42% QoQ because of the same transit delay, compounded by a dip in sales to a major customer in Q4 FY24 that meant no carry-over advantage entering Q1.
- Deferred, not lost: Management indicated unshipped goods in transit were at least 50% of the quarterly turnover, implying a material revenue catch-up in Q2 when those shipments reach customers.
- Freight cost pressure: Ocean freight rates have risen over the last 2–3 months due to longer routes; management expects resolution in about a quarter.
VK Singh: "So, as that being a pure-play CDMO, we are in contact with a lot of innovator companies. And for whatever reason you attribute it to, China plus one or whatever you call it they are tailwinds for Indian companies."
Pharma Intermediates: The Cardiovascular Ramp
- 60% QoQ growth: PI segment surged as commercial supplies to the cardiovascular customer, which began in Q3 FY24, ramped up meaningfully; the new 120 KL capacity commissioned in July 2024 at Unit II, Ambernath (cost ~₹90 cr) is now in validation phase.
- Validation batches passed: The validation batches for the cardiovascular intermediate from the new capacity were successfully executed in July; management expects increased offtake from Q3 onward, with orders already in hand.
- More capacity coming: An additional 70–80 KL in the same block, for a contrast media intermediate for an innovator in the MRI space, is expected to go commercial by Q3, with validation batches to be shipped out around September/October.
- CRAMS pipeline active: The company is actively pursuing 7–8 CRAMS opportunities with innovators or global CDMOs in oncology and CNS, and is in advanced discussions.
- Headcount built ahead of revenue: Employee cost increased marginally due to headcount added for new capacities and corporate functions; this trend is expected to continue for the next 12 months before operating leverage kicks in.
Margins: A Surprising Upside
- 140 bps gross margin improvement: Despite contrast media, the highest-margin segment, falling from 62% to 40% of revenue, gross margin expanded because of a slight reduction in key raw material price for the largest contrast media customer, higher volume of another contrast media product with better margin, and a positive product mix from that building block.
- Inventory accounting tailwind, partially: A technical effect of higher goods in transit, WIP, and finished goods inventoryizing costs gave a marginal boost that will reverse next quarter.
- Depreciation change helped reported earnings: The shift from WDV to straight-line method, after a technical evaluation showed reactors operating at similar capacities uniformly, reduced the depreciation charge from ₹7.7 cr to ₹3.5 cr.
- Margin aspiration: Management aspires to maintain around the same margin levels and be consistent as the mix shifts toward new products, with the target to sustain existing EBITDA and PAT margins; operating leverage could push margins even higher than currently reported.
Shiven Arora: "I think both the product categories are for the innovators. And these are specialized products and as we gain more experience in these categories and the specific products our efficiencies are improving with time. So the aspiration would be around the same margin levels and be consistent in terms of suppliers."
Capacity Build-Out: Saturation Forces a Greenfield
- Existing sites maxed out: Management stated explicitly that existing capacities are saturated, with no further debottlenecking or addition of blocks possible, making a greenfield site necessary.
- Greenfield initiation: A significantly large land parcel is being evaluated; one or two blocks may be ready in a year to a year and a half to further augment capacity.
- Unit III Mahad on track: The warehouse and effluent treatment plant are almost complete; the block for contrast media backward integration is on schedule for commissioning in Q1 FY26.
- Small volume plant restart: Work has recommenced on a small volume plant in Unit II for proof of concept, regulatory filings, and small GMP validation quantities; commissioning expected in Q1 FY26.
- Capex visibility is customer-backed: The ₹200 cr committed spend over 12–18 months is partly for existing customer forecast needs and partly for 3–4 products that are partly commercialized or in validation; much of the capacity is contractually backed.
- Fungible capacity philosophy: Management does not invest based on product category; capacities are fungible by stated policy, which provides flexibility as demand shifts across products.
VK Singh: "So, the greenfield will be required because now existing capacities are saturated. There's no further debottlenecking or addition of blocks in the existing capacities possible."
Contrast Media: The Waiting Game
- Forward integration product near the finish line: The advanced intermediate for an innovator customer has completed validation, use test trials, and stability data, all of which were positive; a supply agreement is in place and a formal PO is described as a matter of time.
- No timeline given: Management acknowledged the molecule is complex and has gone through a series of tests that can cause some delay, but emphasized the customer's sourcing necessity remains; capacities are live and on warm standby.
- APD plant cost advantage: The continuous process technology in the APD plant gives a cost advantage that management believes no competitor has; capacity will exceed captive consumption, opening opportunities beyond internal use.
- Backward integration on schedule: The Unit III block for contrast media backward integration is set for Q1 FY26 commissioning, which will further strengthen the segment's cost position.
Shiven Arora: "There's no specific delay, actually. I think this is a complex molecule and has gone through series of use test trials and validations and stability studies. Things like this typically can have a certain amount of delay, but overall outlook when it comes to this advanced intermediate and the necessity from a sourcing point of view by the customer is there."
VK Singh: "I don't think anybody else has got a continuous process. So I think our costs will be pretty much in control. We'll be one of the industry leaders as far as cost is concerned and there'll be a lot of headroom to fight."
Sweeteners & Other Segments
- Saccharin shift to FMCG: The artificial sweetener business is moving focus to FMCG customers and exiting the spot market, which caused a small impact but is expected to produce more consistent sales going forward.
- New salt launched: Calcium saccharine, a higher-value salt developed for a customer's specific formulation need, has been scaled up and commercialized.
- Annual contracts locked: With FMCG customers, annual contracts have locked in the existing level of operations, providing revenue visibility.
- R&D platforms expanded: New chemistry platforms added include pyrophoric chemistry, iodination, enzymatic, and amino acid platforms, with augmented R&D labs and scientific talent.
- Renewable energy: A solar plant commissioned last year, combined with existing windmills, now generates about 70% of energy from renewable sources.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cardiovascular intermediate ramp | Increased offtake from new 120 KL capacity; orders in hand, validation passed | Q3 FY25 onward |
| MRI contrast media intermediate | Additional 70–80 KL capacity commercial; validation batches shipped | Q3 FY25 (Sep/Oct) |
| Small volume plant | Commissioning for proof of concept, regulatory filings, small GMP quantities | Q1 FY26 |
| Unit III backward integration block | Contrast media backward integration capacity commissioned | Q1 FY26 |
| Committed capex spend | ₹200 cr to be spent | 12–18 months |
| Capacity addition | 40–50% more capacity added | 12–18 months |
| Greenfield site | One or two blocks ready to augment capacity | 1–1.5 years |
| Employee cost trend | Continued headcount additions for new capacities and corporate functions | Next 12 months |
| Freight cost normalization | Ocean freight rates expected to resolve | ~1 quarter |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹163 cr, -11% QoQ |
| EBITDA margin | 27.2% as on Q1 FY25 |
| EBITDA margin (quarterly) | 27%, vs 29% in Q4 FY24 |
| PAT margin | 23%, marginally higher than Q4 FY24 |
| ROCE | 22% annualised basis |
| Fixed asset turnover | over 3x |
| Cash and treasury investments | over ₹380 cr, debt-free |
| Contrast media revenue change | -42% QoQ |
| Pharmaceutical Intermediates revenue growth | 60% growth in Q1 FY25 |
| Gross margin change | improved by 1% QoQ, helped by raw material cost easing and product mix |
| Depreciation | ₹3.5 cr, vs ₹7.7 cr in Q4 FY24, due to change to straight-line method |
| Inventory days | 204 days, up from 136 days in Q4 FY24, predominantly due to goods in transit |
| Capex capitalised in Q1 | ₹90 cr |
| Committed capex pipeline | ₹200 cr to be spent over 12–18 months |
| Capacity utilisation | 70%–75% |
| Manpower expense change | up 14% QoQ |
| Goods in transit not recognised as revenue | more than at least 50% of quarterly turnover, analyst computed ~₹80 cr |
| Ocean freight transit time | 60–65 days, up from 35–40 days previously |